glp-1 receptor agonist nephrolithiasis glp-1_analogs [TUSOM Frontiers | GLP−1 receptor agonists
Description
November 2023 : Eli Lilly received US FDA approval for ZEPBOUND, an obesity treatment that activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors
The empagliflozin group achieved a mean weight loss of 3.6 kg and 3.8 kg in the two analyses, respectively
Fiber-rich foods, legumes, and fermented items like curd
Frontiers in Endocrinology
Cardiovascular data on endpoints like MACE-3 or MACE-4 are presently not available yet, but an early meta-analysis demonstrated at least cardiovascular safety in patients with T2D treated with tirzepatide (78, 79)
